Creative Animodel is specialized in providing an integrated portfolio of leukemia models to improve the molecular understanding and treatment of leukemia. With advanced facilities and technologies, we have strong expertise in developing disease models suited for testing disease-modifying compounds or drugs. What’s more, customized leukemia models can be designed and ordered on your demand.
The Severe Challenge from Leukemia
Leukemia is a group of cancers that commonly begins in the bone marrow and results in numerous abnormal white blood cells. The common symptoms of leukemia may include feeling tired, fever, pain in the bone or joints, increased the risk for infections, bleeding and bruising problems. Leukemia can bring about significant morbidity and mortality. In 2015, 2.3 million people were diagnosed with leukemia and 353,500 people died from it. Four types of leukemias account for 85% deaths from leukemias, which are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).
Until now, there is no effective way to prevent leukemia. The treatment of leukemia can be complex, likely involving chemotherapy, radiation therapy, targeted therapy, and bone narrow transplant. According to statistical data from SEER 18 2007-2013, approximately 60.6% people survive more than 5 years after being diagnosed with leukemia. Faced the severe challenge from leukemia, scientists are striving to better understand the underlying mechanisms and cure patients suffering from leukemia.
Figure 1. The difference between healthy people and patients with leukemia.
Our Featured Leukemia Models
To better comprehend leukemia and ultimately treat patients diagnosed with the disease, Creative Animodel strives to develop the most advanced and instructive leukemia models. The stringent model validation and quality control are necessary to ensure the reliability of the models for efficacy testing. Leukemia models are established via genetic fingerprinting, consistent tumor growth monitoring and other strategies.
> Xenograft Models
We offer diverse immunocompromised models with varying genetic backgrounds and treatment histories for analyzing the effectiveness of drug candidates to treat leukemia, such as NSGTM-SGM3, the most effective engrafts in human leukemia researches.
Figure 2. Xenograft models development process. Primary patient samples or human cell lines can be directly injected into immunocompromised host animals. Host animals are frequently exposed to ionizing radiation prior to sample injection to suppress any residual immune function.
• Patient-derived xenograft (PDX)
We provide patient-derived xenograft (PDX) models genetically characterized for efficacy testing to advance your leukemia research. The PDX models, in which human tumor tissue or cell lines are introduced, are powerful tools for investigating the interactions between human immune system and human leukemia.
• Heterogeneous xenograft
We provide diverse effective heterogeneous xenograft models for efficacy testing of your new drugs. Our comprehensive heterogeneous leukemia cell lines include U937, THP-1, MV-4-11, HEL, TF-1a, ML-2, HL-60, K562, KARPAS-299, Daudi, RL, Mino, Raji, Ramos, ARH-77, KMS-12-BM, KG-1, JeKo-1, MAVER-1, CML-T1, MOLM-13, Nalm-6, etc.
• Homogeneous xenograft
We provide several instructive homogeneous models for your leukemia research. Our comprehensive homogenous leukemia cell lines involve C1498, L1210 and WEHI-3.
> Transgenic Models
We develop leukemia transgenic models via manipulation of embryonic stem (ES) cells (microinjection or electroporation), cre recombinase (in a tissue-specific manner) and other techniques to improve the understanding of leukemia at genetic level. The customized transgenic models are developed on your demand.
Creative Animodel, as a preclinical Contract Research Organization (CRO), has spent decades of efforts to provide specialty pharmacology services in human diseases. Our state-of-the-art facility and specialized knowledge enhance our capabilities to optimize and exploit disease models to advance the pharmaceutical industries.
Cook, G.J.; Pardee, T.S. Animal models of leukemia: any closer to the real thing?. Cancer and Metastasis Reviews. 2013, 32(1-2): 63-76.